VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers

Sci Immunol. 2019 Nov 8;4(41):eaay0555. doi: 10.1126/sciimmunol.aay0555.

Abstract

Although immune checkpoint blockade therapies have demonstrated clinical efficacy in cancer treatment, harnessing this strategy is largely encumbered by resistance in multiple cancer settings. Here, we show that tumor-infiltrating T cells are severely exhausted in the microsatellite stable (MSS) colorectal cancer (CRC), a representative example of PD-1 blockade-resistant tumors. In MSS CRC, we found wound healing signature to be up-regulated and that T cell exhaustion is driven by vascular endothelial growth factor-A (VEGF-A). We report that VEGF-A induces the expression of transcription factor TOX in T cells to drive exhaustion-specific transcription program in T cells. Using a combination of in vitro, ex vivo, and in vivo mouse studies, we demonstrate that combined blockade of PD-1 and VEGF-A restores the antitumor functions of T cells, resulting in better control of MSS CRC tumors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Caco-2 Cells
  • Colorectal Neoplasms / immunology*
  • Colorectal Neoplasms / pathology
  • High Mobility Group Proteins / immunology*
  • Homeodomain Proteins / immunology*
  • Humans
  • Mice
  • Mice, Inbred C57BL
  • Microsatellite Repeats / immunology
  • Programmed Cell Death 1 Receptor / immunology*
  • T-Lymphocytes / immunology*
  • Vascular Endothelial Growth Factor A / immunology*

Substances

  • High Mobility Group Proteins
  • Homeodomain Proteins
  • PDCD1 protein, human
  • Pdcd1 protein, mouse
  • Programmed Cell Death 1 Receptor
  • Rhox8 protein, mouse
  • TOX protein, human
  • Vascular Endothelial Growth Factor A